Abstract
Vaspin is a novel adipocytokine that has potential insulin-sensitizing effects. The aim of this study is to explore the role of vaspin in the progression of type 2 diabetes mellitus (T2DM) in humans through a longitudinal process. This was a 2-year follow-up study that included 132 patients with T2DM and 170 non-diabetic subjects. The serum vaspin and adiponectin levels were determined with ELISA. Anthropometric measurements, circulating glucose, hemoglobin A1c, insulin level, liver function, kidney function, and lipid profile were measured for each participant. The new onset of T2DM was counted in non-diabetic subjects and the glycemic control was analyzed in T2DM patients at follow-up. At enrollment, the serum vaspin and adiponectin levels were lower in T2DM patients compared with non-diabetic subjects. Significant positive correlation between serum vaspin and HDL-C levels (r = 0.23, P = 0.006) was observed in non-diabetic controls. The serum vaspin concentration was also significantly correlated with body mass index (BMI) (r = 0.19, P = 0.028), waist-hip ratio (WHR) (r = 0.17, P = 0.035) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.14, P = 0.029) in T2DM patients. In cohort analyses, it was found that lower serum vaspin [odds ratio (OR) = 0.52, 95% confidence interval (CI): 0.10–0.87, P = 0.015] and adiponectin (OR = 0.35, 95% CI: 0.20–0.72, P = 0.015) levels at baseline were risk factors for new onset of T2DM at follow-up. The percentage of insulin treatment in T2DM patients was higher in the sub-group with lower serum vaspin level than that in the sub-group with higher vaspin level at follow-up (55.3% vs. 44.7%, P = 0.020). Our study indicates that low serum concentration of vaspin is a risk factor for the progression of T2DM.
Highlights
Adipose tissue is an inert energy-storing tissue, and an active endocrine organ [1], which secrets many kinds of adipocytokines, such as adiponectin, leptin, TNF-a and so on
The role of vaspin in glycemic control in diabetic patients has not been addressed in previous studies. In this 2.0-year follow-up study, our aims were to examine 1) whether serum vaspin levels are associated with adiposity and insulinresistance; 2) whether non-diabetic subjects with lower serum vaspin levels are more susceptible to developing type 2 diabetes mellitus (T2DM); 3) whether lower vaspin levels are concomitant with poorer glycemic control in T2DM
Our longitudinal study analyzed the independent roles of vaspin and adiponectin in the incidence of T2DM in non-diabetic subjects and long-time glycemic control in patients with T2DM
Summary
Adipose tissue is an inert energy-storing tissue, and an active endocrine organ [1], which secrets many kinds of adipocytokines, such as adiponectin, leptin, TNF-a and so on. Recent studies found that vaspin gene expression in human adipose tissue and circulating vaspin levels were positively associated with obesity-associated diseases and T2DM [13,14,15,16]. It is indicated that vaspin plays a role in adipoinsular axis, and may be associated with insulin resistance in obese subjects, including patients with T2DM and polycystic ovary syndrome [13]. All these data suggest that vaspin may be involved in the glucose metabolism and the development of T2DM in human. It is still unclear what the real role of vaspin is in the progression of diabetes in a longitudinal process
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
